Clinical Medicine VI.
Varga, Noémi
IW3OZT
Semmelweis University Department of Dermatology, Venereology and Dermatooncology
+36203123010
98mimma@gmail.com
Comparison of Optically Guided High-Frequency Ultrasound and Multispectral Imaging for the Estimation of Tumor Thickness of Malignant Melanoma
Noémi Nóra Varga1, Phyllida Hamilton-Meikle1, Szabolcs Bozsányi1,4, Klára Farkas1, Boglárka Szabó1, Flóra Vasanits1, Lili Gulyás1, András Bánvölgyi1, Kende Lőrincz1, Ilze Lihacova2, Alexey Lihachev2, Emilija Vija Plorina2, Enikő Kuroli1,3, György Paragh4, Péter Holló1, Norbert M. Wikonkál1, Márta Medvecz1 and Norbert Kiss1
1 Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary
2 Biophotonics Laboratory, Institute of Atomic Physics and Spectroscopy, University of Latvia, Riga, Latvia
3 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
4 Department of Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Szóbeli
Clinical Medicine VI.
English
Clinical Medicine
Introduction: The incidence of malignant melanoma has shown a significant increase in recent decades. Histopathological evaluation after surgical excision is the gold standard method for diagnosing melanoma. Based on the Breslow thickness, the histologically confirmed tumor depth, the clinicians define the required staging procedures and surgical safety margins. However, Breslow thickness is not available at the time of the initial melanoma diagnosis. To date, novel imaging techniques have been introduced for the assessment of Breslow thickness, but no data is available to compare their efficacy.
Aims: In this work, we aimed to evaluate and compare the efficacy of optically guided high-frequency ultrasound (HFUS) and multispectral imaging (MSI) for the estimation of Breslow tumor thickness and tumor staging before surgery.
Method: In this study, we examined 80 patients with histologically verified primary melanoma. We created 3 subgroups of the patients according to tumor thickness, which also define the required safety margins: Breslow≤1 mm, 1-2 mm and >2 mm. We used an optically guided 33 MHz HFUS device (Dermus SkinScanner) and an MSI prototype to measure tumor thickness. Image analysis was performed using SkinAid (HFUS) and ImageJ (MSI) software.
Results: The used MSI algorithm allowed us to classify melanomas into the above-mentioned three subgroups with the sensitivity of 57.70% and the specificity of 78.80%. We compared these results to the performance of HFUS, which reached a sensitivity of 93.50% and specificity of 96.75%. Both correlations were significant, however HFUS showed a closer correlation with Breslow thickness than MSI (MSI: r: -0.6788; HFUS: r: 0.9706, p: <0.0001).
Conclusion: To the best of our knowledge, we were the first to analyze tumor thickness using MSI to classify melanomas into 3 subgroups of great clinical relevance. However, our novel optically guided HFUS reached higher sensitivity and specificity. Based on our findings, these novel imaging methods may help to estimate Breslow thickness prior to surgery to guide the further management of the patients.
Funding: This work was supported by grants from the EFOP-3.6.3-VEKOP-16-2017-00009 (N.N.V.), ÚNKP-22-2-III-SE-18 (N.N.V.), ÚNKP-22-4-II-SE-13 (N.K.) and the National Research, Development and Innovation Office of Hungary – NKFIH [FK131916, Semmelweis University, M.M.].
Semmelweis University, Károly Rácz Doctoral School of Clinical Medicine
Dr. Norbert Kiss
I give consent to the publication of my abstract on the website of the congress.
Szabad
elfogadva
szóbeli
nem rendelkezett róla
6832
10:15
10:30
Noémi Nóra Varga1, Phyllida Hamilton-Meikle1, Szabolcs Bozsányi1,4, Klára Farkas1, Boglárka Szabó1, Flóra Vasanits1, Lili Gulyás1, András Bánvölgyi1, Kende Lőrincz1, Ilze Lihacova2, Alexey Lihachev2, Emilija Vija Plorina2, Enikő Kuroli1,3, György Paragh4, Péter Holló1, Norbert M. Wikonkál1, Márta Medvecz1 and Norbert Kiss1
1 Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary
2 Biophotonics Laboratory, Institute of Atomic Physics and Spectroscopy, University of Latvia, Riga, Latvia
3 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
4 Department of Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States